BIOTRONIK - SaFety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III Austria.
Phase of Trial: Phase IV
Latest Information Update: 04 Oct 2017
Price : $35 *
At a glance
- Drugs Sirolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms BIOFLOW-III Austria
- Sponsors BIOTRONIK
- 11 Apr 2016 Status changed from active, no longer recruiting to completed.
- 07 Sep 2015 Planned End Date changed from 1 Feb 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
- 02 Feb 2015 Planned End Date changed from 1 Oct 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov.